PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease

The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene therapy Kebilidi for AADC deficiency. It is the first approved gene therapy to be delivered directly to the brain.